BG104813A - Заместени индолинони с инхибиращ ефект върху кинази и комплекси циклин/cdk - Google Patents

Заместени индолинони с инхибиращ ефект върху кинази и комплекси циклин/cdk

Info

Publication number
BG104813A
BG104813A BG104813A BG10481300A BG104813A BG 104813 A BG104813 A BG 104813A BG 104813 A BG104813 A BG 104813A BG 10481300 A BG10481300 A BG 10481300A BG 104813 A BG104813 A BG 104813A
Authority
BG
Bulgaria
Prior art keywords
cycline
kinases
cdk complexes
inhibiting effect
substituted indolinones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BG104813A
Other languages
English (en)
Other versions
BG64443B1 (en
Inventor
Armin Heckel
Rainer Walter
Wolfgang Grell
Meel Jacobus Van
Norbert Redemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of BG104813A publication Critical patent/BG104813A/bg
Publication of BG64443B1 publication Critical patent/BG64443B1/bg
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Изобретението се отнася до заместени индолинони собща формула@@в която R1 до R5 и Х имат значенията, посочени в описанието, до изомерите и солите им, по-специално до техни физиологично приемливи соли. Съединенията съгласно изобретението имат ценни фармакологични свойства, по-специално инхибиращ ефект върху различни кинази и комплекси циклин/CDK ивърху пролиферацията на различни туморни клетки. Изобретението се отнася също до лекарствени средства, съдържащи съединенията, до използването им и до методи за тяхното получаване.
BG104813A 1998-04-15 2000-09-29 Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes Active BG64443B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19816624A DE19816624A1 (de) 1998-04-15 1998-04-15 Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (2)

Publication Number Publication Date
BG104813A true BG104813A (bg) 2001-08-31
BG64443B1 BG64443B1 (en) 2005-02-28

Family

ID=7864562

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104813A Active BG64443B1 (en) 1998-04-15 2000-09-29 Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes

Country Status (31)

Country Link
EP (1) EP1071665B1 (bg)
JP (1) JP4015365B2 (bg)
KR (1) KR100588250B1 (bg)
CN (1) CN100338036C (bg)
AR (1) AR015763A1 (bg)
AT (1) ATE251138T1 (bg)
AU (1) AU749829B2 (bg)
BG (1) BG64443B1 (bg)
BR (1) BR9909688A (bg)
CA (1) CA2323111C (bg)
CO (1) CO5011040A1 (bg)
DE (2) DE19816624A1 (bg)
DK (1) DK1071665T3 (bg)
EA (1) EA003532B1 (bg)
EE (1) EE04432B1 (bg)
ES (1) ES2207209T3 (bg)
HU (1) HUP0101568A3 (bg)
ID (1) ID26420A (bg)
IL (1) IL138036A0 (bg)
MY (1) MY122357A (bg)
NO (1) NO317298B1 (bg)
NZ (1) NZ507967A (bg)
PL (1) PL343314A1 (bg)
PT (1) PT1071665E (bg)
SK (1) SK283824B6 (bg)
TR (1) TR200002980T2 (bg)
TW (1) TW510897B (bg)
UA (1) UA63009C2 (bg)
WO (1) WO1999052869A1 (bg)
YU (1) YU59800A (bg)
ZA (1) ZA200004623B (bg)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
DE19924401A1 (de) * 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2001016130A1 (de) * 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituierte indolinone als tyrosinkinase inhibitoren
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1294688A2 (en) 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2002303892A1 (en) 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
CN1633296A (zh) 2002-03-26 2005-06-29 贝林格尔·英格海姆药物公司 糖皮质素模拟物、其制备方法、药物组合物及其用途
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
EP1670789B1 (en) 2003-10-03 2008-11-19 Boehringer Ingelheim Pharmaceuticals Inc. Fluorescent probes for use in protein kinase inhibitor binding assay
DE102004012070A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
ES2326907T3 (es) 2004-12-27 2009-10-21 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y su uso.
ES2348099T3 (es) * 2005-06-10 2010-11-30 Merck Patent Gmbh Oxindoles como inhibidores de cinasa.
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
WO2008070507A2 (en) 2006-12-06 2008-06-12 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
MX2010013095A (es) 2008-06-06 2010-12-21 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
JP6072058B2 (ja) * 2011-11-14 2017-02-01 リガンド・ファーマシューティカルズ・インコーポレイテッド 顆粒球コロニー刺激因子受容体と結合する方法および組成物
US9962370B2 (en) * 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
CN107033064B (zh) * 2017-04-28 2019-07-09 西安医学院 一种3-(吗啉取代芳亚胺基)吲哚类化合物及其制备方法和应用
CN111285872B (zh) * 2018-12-06 2022-05-17 北京志健金瑞生物医药科技有限公司 吲哚-2-酮衍生物及其制备方法与用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу

Also Published As

Publication number Publication date
HUP0101568A3 (en) 2002-12-28
CO5011040A1 (es) 2001-02-28
BG64443B1 (en) 2005-02-28
WO1999052869A1 (de) 1999-10-21
EE04432B1 (et) 2005-02-15
UA63009C2 (en) 2004-01-15
BR9909688A (pt) 2000-12-19
EA003532B1 (ru) 2003-06-26
CA2323111C (en) 2009-09-15
NO20005151L (no) 2000-10-13
EE200000598A (et) 2002-04-15
HUP0101568A2 (hu) 2001-09-28
JP4015365B2 (ja) 2007-11-28
SK15132000A3 (sk) 2001-03-12
IL138036A0 (en) 2001-10-31
ZA200004623B (en) 2001-05-30
EP1071665B1 (de) 2003-10-01
NO20005151D0 (no) 2000-10-13
CN1297438A (zh) 2001-05-30
DE59907199D1 (de) 2003-11-06
JP2002511449A (ja) 2002-04-16
TW510897B (en) 2002-11-21
CN100338036C (zh) 2007-09-19
AU3814999A (en) 1999-11-01
AR015763A1 (es) 2001-05-16
EP1071665A1 (de) 2001-01-31
SK283824B6 (sk) 2004-02-03
DK1071665T3 (da) 2004-01-05
TR200002980T2 (tr) 2001-02-21
MY122357A (en) 2006-04-29
YU59800A (sh) 2003-04-30
ES2207209T3 (es) 2004-05-16
KR100588250B1 (ko) 2006-06-13
PL343314A1 (en) 2001-08-13
PT1071665E (pt) 2004-02-27
CA2323111A1 (en) 1999-10-21
DE19816624A1 (de) 1999-10-21
NO317298B1 (no) 2004-10-04
ID26420A (id) 2000-12-21
NZ507967A (en) 2003-04-29
KR20010042731A (ko) 2001-05-25
AU749829B2 (en) 2002-07-04
EA200001021A1 (ru) 2001-06-25
ATE251138T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
BG104813A (bg) Заместени индолинони с инхибиращ ефект върху кинази и комплекси циклин/cdk
BG104938A (bg) Заместени индолинони, тяхното получаване и тяхното приложение като лекарствени средства
BG104996A (bg) Индолови производни и приложението им при лечениена злокачествени и други заболявания причинени отпатологична клетъчна пролиферация
MY127956A (en) Substituted indolines which inhibit receptor tyrosine kinases
AP1553A (en) Tricyclic inhibitors of poly (ADP-Ribose) polymerases.
BG105327A (bg) Нови заместени индолинони с инхибиращо действие върху различни кинази и комплекси циклин/cdk
BG105784A (bg) Триазоли с допамин-d3 рецепторен афинитет
AU3804500A (en) 2-amino-6-anilino-purines and their use as medicaments
JO2248B1 (en) Pirazolobenzodiazepines
BG101110A (bg) Заместени пиримидинови съединения и тяхното използване
CA2396865A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
ZA975439B (en) New pyridyl alkane acid amides.
WO2001027080A3 (de) In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren
DE69907419D1 (en) Antitumorwirkstoffe
AU1044500A (en) Imidazonaphthyridines
SE0203070D0 (en) Novel compounds
RS20050047A (en) Indoline derivatives substituted in position 6,production and use thereof as medicaments
GR3001035T3 (en) Heterocyclic tetrahydro-3,4-diamine-n-n'-platinum complexes
AU2910800A (en) Novel substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines
BG105549A (bg) Използване на n-заместени азабициклоалканови производни за лечение на заболявания на централната нервна система
TW377353B (en) Purine derivatives and process for their preparation
GR3024709T3 (en) Novel cytarabine derivatives, their production and use